Stroke Care, a China-based stroke therapy product developer backed by conglomerate Fosun and outboard motor manufacturer Hidea, has secured an eight-figure dollar amount of series C funding, DealStreetAsia reported yesterday.
Healthcare investment firm Sherpa Healthcare Partners and private equity firm Lyfe Capital supplied the funding, two months after an investment of undisclosed size by SDIC Unity Capital, part of the Chinese state-owned State Development and Investment Corporation.
Founded in 2016, Stroke Care is working on technology that will assist in cerebral therapy for stroke patients. The series C proceeds will fund further development of five products in its pipeline.
The company had raised undisclosed amounts in 2018 angel and series A rounds that both included Fosun subsidiary Fosun Pharma, according to DealStreetAsia. It added about $11m in series B funding from Hidea, Changjiang Yangtze Capital and Sharewin Investment the following year.
